Positive CHMP vote for Nuedexta
This article was originally published in Scrip
Executive Summary
Avanir Pharmaceuticals has received a positive recommendation from the European Medicines Agency's CHMP to market Nuedexta for the treatment of pseudobulbar affect, irrespective of neurologic cause.